Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Sockel

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
Annals of Hematology|January 12, 2024
VEXAS syndrome: complete molecular remission after hypomethylating therapyKatja Sockel, Katharina Götze, Christina Ganster, et al.
Blood Advances|October 20, 2021
The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemiaVladan Vucinic, Leo Ruhnke, Katja Sockel, et al.
Haematologica|September 7, 2014
Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemiaUwe Platzbecker, Katja Sockel, Claudia Schönefeldt, et al.
Haematologica|September 7, 2012
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trialKatja Sockel, Martin Bornhaeuser, Eva Mischak-Weissinger, et al.
Leukemia|September 9, 2021
Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smearsJan-Niklas Eckardt, Jan Moritz Middeke, Sebastian Riechert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2012
MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantationMartin Wermke, Anne Schmidt, Jan Moritz Middeke, et al.
Stem Cells (Dayton, Ohio)|September 30, 2015
Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term OutcomeFelix von Dalowski, Michael Kramer, Martin Wermke, et al.
Blood Advances|March 23, 2022
Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AMLSebastian Stasik, Clara Burkhard-Meier, Michael Kramer, et al.
Leukemia & Lymphoma|May 17, 2017
Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemiaBozena Büttner, Holger Knoth, Michael Kramer, et al.
Therapeutic Advances in Hematology|September 2, 2022
Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantationDesiree Kunadt, Sylvia Herold, David Poitz, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
Annals of Hematology|January 12, 2024
VEXAS syndrome: complete molecular remission after hypomethylating therapyKatja Sockel, Katharina Götze, Christina Ganster, et al.
Blood Advances|October 20, 2021
The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemiaVladan Vucinic, Leo Ruhnke, Katja Sockel, et al.
Haematologica|September 7, 2014
Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemiaUwe Platzbecker, Katja Sockel, Claudia Schönefeldt, et al.
Haematologica|September 7, 2012
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trialKatja Sockel, Martin Bornhaeuser, Eva Mischak-Weissinger, et al.
Leukemia|September 9, 2021
Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smearsJan-Niklas Eckardt, Jan Moritz Middeke, Sebastian Riechert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2012
MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantationMartin Wermke, Anne Schmidt, Jan Moritz Middeke, et al.
Stem Cells (Dayton, Ohio)|September 30, 2015
Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term OutcomeFelix von Dalowski, Michael Kramer, Martin Wermke, et al.
Blood Advances|March 23, 2022
Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AMLSebastian Stasik, Clara Burkhard-Meier, Michael Kramer, et al.
Leukemia & Lymphoma|May 17, 2017
Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemiaBozena Büttner, Holger Knoth, Michael Kramer, et al.
Therapeutic Advances in Hematology|September 2, 2022
Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantationDesiree Kunadt, Sylvia Herold, David Poitz, et al.
Pageof 10